Drugs / SIRT-Y90
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06867432 | Mar 2025 → Mar 2026 overdue | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIRT-Y90 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06867432 ↗ |
| Route | Other | “infused after hepatic arterial catheterization, tumor donor artery” NCT06867432 ↗ |